Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
RecruitingObservational study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Migraine diagnosis according to ICHD-III. * Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations. * Signature of informed consent. Exclusion Criteria: * Presence of headache different from migraine. * Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.
About the study
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
What is being tested
- CGRP antibody or gepant (drug)
Sponsor: Hospital Universitari Vall d'Hebron Research Institute · Participants: 700 · Started: Jan 2, 2024
Contact the study team
- Patricia Pozo-Rosich, MD, PhD · Phone: (+34) 93 489 30 00
- Edoardo Caronna, MD, PhD · Phone: (+34) 93 489 30 00
Official record on ClinicalTrials.gov — NCT07159750
Locations in the U.S.
| Florida | University of Miami, Miller School of Medicine, Miami |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.